These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 9105581)

  • 1. Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats.
    Khromova I; Voronina T; Kraineva VA; Zolotov N; Männistö PT
    Behav Brain Res; 1997 Jun; 86(1):49-57. PubMed ID: 9105581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolcapone, an inhibitor of catechol O-methyltransferase, counteracts memory deficits caused by bilateral cholinotoxin lesions of the basal nuclei of Meynert.
    Khromova I; Rauhala P; Zolotov N; Männistö PT
    Neuroreport; 1995 May; 6(8):1219-22. PubMed ID: 7662912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats.
    Liljequist R; Haapalinna A; Ahlander M; Li YH; Männistö PT
    Behav Brain Res; 1997 Jan; 82(2):195-202. PubMed ID: 9030401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
    Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
    Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice.
    Detrait ER; Carr GV; Weinberger DR; Lamberty Y
    Behav Pharmacol; 2016 Aug; 27(5):415-21. PubMed ID: 26919286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
    Li YH; Wirth T; Huotari M; Laitinen K; MacDonald E; Männistö PT
    Eur J Pharmacol; 1998 Sep; 356(2-3):127-37. PubMed ID: 9774242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
    Gerlach M; Xiao AY; Kuhn W; Lehnfeld R; Waldmeier P; Sontag KH; Riederer P
    J Neural Transm (Vienna); 2001; 108(2):189-204. PubMed ID: 11314772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catechol O-methyltransferase: characterization of the protein, its gene, and the preclinical pharmacology of COMT inhibitors.
    Männistö PT
    Adv Pharmacol; 1998; 42():324-8. PubMed ID: 9327906
    [No Abstract]   [Full Text] [Related]  

  • 9. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
    Gerlach M; Ukai W; Ozawa H; Riederer P
    J Neural Transm (Vienna); 2002 May; 109(5-6):789-95. PubMed ID: 12111468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases.
    Lv X; Wang XX; Hou J; Fang ZZ; Wu JJ; Cao YF; Liu SW; Ge GB; Yang L
    Toxicol Appl Pharmacol; 2016 Jun; 301():42-9. PubMed ID: 27089846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
    Kaakkola S; Gordin A; Männistö PT
    Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone].
    Arnold G; Kupsch A
    Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of co-administration of catechol-O-methyltransferase inhibitors and L-dihydroxyphenylalanine in rat models of depression.
    Männistö PT; Lang A; Rauhala P; Vasar E
    Eur J Pharmacol; 1995 Feb; 274(1-3):229-33. PubMed ID: 7768276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-training nucleus basalis magnocellularis functional tetrodotoxin blockade effects on passive avoidance consolidation in the rat.
    Ambrogi Lorenzini C; Baldi E; Bucherelli C; Tassoni G
    Behav Brain Res; 1994 Apr; 61(2):191-6. PubMed ID: 8037866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of extinction by scopolamine.
    Prado-Alcalá RA; Haiek M; Rivas S; Roldan-Roldan G; Quirarte GL
    Physiol Behav; 1994 Jul; 56(1):27-30. PubMed ID: 8084904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.
    De Santi C; Giulianotti PC; Pietrabissa A; Mosca F; Pacifici GM
    Eur J Clin Pharmacol; 1998 May; 54(3):215-9. PubMed ID: 9681662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed matching-to-sample performance by rats in a new avoidance-motivated maze: response to scopolamine and fimbria-fornix lesions.
    Bresnahan EL; Wiser PR; Muth NJ; Ingram DK
    Physiol Behav; 1992 Apr; 51(4):735-46. PubMed ID: 1594672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible involvement of central cholinergic system in ameliorating effects of indeloxazine, a cerebral activator, on disturbance of learning behavior in rats.
    Yamamoto M; Takahashi K; Ohyama M; Sasamata M; Yatsugi S; Okada M; Endoh H
    Prog Neuropsychopharmacol Biol Psychiatry; 1994 May; 18(3):603-13. PubMed ID: 8078992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
    Forester SC; Lambert JD
    Carcinogenesis; 2014 Feb; 35(2):365-72. PubMed ID: 24148818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.